Drug CategoryDrugIHD Dosing

Administration Timing Around HD Session

AntifungalsVoriconazole200mg PO Q12H; IV not recommendedAdminister Anytime During HD

Molecular Weight    (Da)

Excreted Unchanged (%)Normal Half-Life (Hours)ESRD Half-Life (Hours)Plasma Protein Binding (%)Volume of Distribution (L/kg)Dialytic Plasma Clearance (ml/min)% Dialyzed
349<26-24N/A604.666.710 (high flux)


  • Aronoff GR, Bennett WM, Berns JS, Brier ME, Kasbekar N, Mueller BA, et al. Drug Prescribing in Renal Failure. Philadelphia: American College of Physicians;2007.
  • Cota J, Burgess D. Antifungal Dose Adjustment in Renal and Hepatic Dysfunction : Pharmacokinetic and Pharmacodynamic Considerations. Curr Fungal Infect Rep 2010; 4, 120-128.
  • DrugBank [Online]. 2012 Apr 12 [cited 2012 May 6]; Available from: URL: http://www.drugbank.ca/drugs/DB00582
  • Hafner V, Czock D, Burhenne J et al. Pharmacokinetics of sulfobutylether-beta-cyclodextrin and voriconazole in patients with end-stage renal failure during treatment with two hemodialysis systems and hemodiafiltration. Antimicrobial agents and chemotherapy 2010; 54(6), 2596-602.
  • Heintz B, Matzke G, Dager W. Antimicrobial dosing concepts and recommendations for critically ill adult patients receiving continuous renal replacement therapy or intermittent hemodialysis. Pharmacotherapy 2009; 29(5), 562-77.
  • Ullmann A. Pharmacological Aspects of the New Triazole Voriconazole. Annals of Hematology, S50.